the potential of mrd as a surrogate marker in randomized trials to accelerate drug approvals
Published 1 year ago • 105 plays • Length 3:35Download video MP4
Download video MP3
Similar videos
-
3:57
the possibility of using mrd as a surrogate endpoint for pfs and os in myeloma clinical trials
-
1:38
using mrd as an endpoint in clinical trials
-
2:17
opinion: value of mrd as an endpoint in hem-onc clinical trials
-
12:59
acute leukemias: is mrd already a surrogate for survival?
-
7:39
understanding mrd
-
1:05:07
euretina case club with prof adnan tufail (nov 10th, 2021)
-
19:03
the era of precision oncology | dr. jaime l. schneider
-
6:33
mrd as a tool to discontinue therapy in mm?
-
3:22
the impact of mrd as a biomarker
-
2:35
mrd focus: why measurable residual disease testing is the future
-
2:03
updated fda mrd guidelines for hematological malignancies
-
2:03
prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy
-
3:05
mrd negativity assessed by flow cytometry associated with improved outcomes in npm1-mutated aml
-
3:35
minimal residual disease (mrd) as a prognostic factor for acute myeloid leukemia (aml)
-
3:03
quantum-first: flt3-itd-specific mrd to assess benefits of quizartinib in flt3-itd aml
-
1:37
mrd in myeloma
-
1:09
taking mrd from trials to the clinic
-
0:44
the clinical meaning of mrd below the threshold of mcr in aml
-
1:49
bringing precision medicine and mrd into clinical strategies
-
1:53
the future of multiple myeloma treatment
-
0:57
potential approval of quizartinib in aml & its place in the aml treatment regimen